Abstract 290P
Background
Dexrazoxane (DXZ) is indicated as a cardioprotective agent for elderly aggressive lymphoma receiving doxorubicin. Several studies reported an apparent increase in the severity of myelosuppression when dexrazoxane was used. Prophylactic use of pegylated granulocyte colony stimulating factor (PEG G-CSF) is known to reduce the incidence of both neutropenia and febrile neutropenia. We conducted a retrospective study to evaluate prophylactic effect of PEG G-CSF in elderly aggressive lymphoma treated with CHOP-based regimen and cardioprotective dexrazoxane.
Methods
We retrospectively analyzed hematological toxicity data from 263 consecutive aggressive lymphoma patients who received a CHOP-based regimen between February 2010 and December 2021. Of these, 68 received dexrazoxane concurrently with the CHOP-based treatment. The differences between incidence of any of the explored outcomes were assessed according to the Fisher exact test.
Results
The median age at diagnosis was 77 (range; 70-87) year-old. Fifty-two patients (76.4%) were diagnosed with diffuse large B-cell lymphoma and treated with R-CHOP therapy. Bone marrow involvement was observed in seven patients (10.3%). Dose reduction (DR) was performed in all patients, as follows: 20% DR in 14 patients, 25% DR in 36 patients, 30% DR in 14 patients, and 40% DR in 4 patients. Treatment-related mortality occurred in 16 patients (23.5%). Grade III/IV neutropenia was developed with an incidence of 25.2% in the patients. Febrile neutropenia developed in 17 patients (25%) with an overall incidence of 8.0% (32/424 cycles) in the cycles. Compared with the non-PEG G-CSF group, PEG G-CSF treatment was associated with significantly lower rate of grade 3/4 hematological toxicities; leukopenia (66.5% vs. 10.7%; P=0.0001), neutropenia (69.6% vs. 16.1%; P=0.0001), febrile neutropenia (34.3% vs. 6.3%; P=0.0003).
Conclusions
Adding DXZ to CHOP-based therapy in elderly aggressive lymphoma patients leads to higher rates of bone marrow suppression in neutropenia as well as to more frequent events of febrile neutropenia. However, PEG G-CSF prophylaxis was effective in reducing the incidence of neutropenia and febrile neutropenia in patients with DXZ prophylaxis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer
Presenter: Chung Tin Justin Ma
Session: Poster viewing 04
282P - Nutritional status and nutritional therapy of common cancer in a cancer hospital of Southwest China
Presenter: Huiqing Yu
Session: Poster viewing 04
283P - Comparative analysis of osteoporotic fracture (OF) and pathologic fracture (PF) in patients with metastatic colorectal cancer (mCRC) who received palliative chemotherapy
Presenter: Yejee Lim
Session: Poster viewing 04
284P - Gut microbiota mediates the protective effects of resveratrol against the intestinal barrier dysfunction in non-alcoholic steatohepatitis induced by high-fat diet
Presenter: Haoyang Cao
Session: Poster viewing 04
285P - Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients
Presenter: Aditya Sarin
Session: Poster viewing 04
286P - Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
Presenter: Amy Body
Session: Poster viewing 04
287P - Long-term yoga enhances the quality of life and symptomatic scale in breast cancer patients undergoing treatment
Presenter: Mayank Jain
Session: Poster viewing 04
288P - Impact of hormonal contraception on estradiol and progesterone serum levels: A 6-year study on progression-free survival, disease-free survival, and overall survival at Dr. Moewardi Hospital
Presenter: Widyanti Soewoto
Session: Poster viewing 04
289P - Cancer cachexia following breast cancer (BC) chemotherapy was associated with clinical stage, number of chemotherapy cycles, and vitamin D concentration
Presenter: Susanna Hutajulu
Session: Poster viewing 04
291P - Assessment of nutritional status in cancer patients using patient generated subjective global assessment screening tool
Presenter: Anuj K. C.
Session: Poster viewing 04